5 Horizons Ventures

Too many groundbreaking therapies never reach clinical trials—not because they don’t work, but because they lack the right funding, strategic execution, and regulatory guidance. At 5 Horizons, we’re changing that. Funding. Strategy. Execution. Accelerated. We provide early-stage biotech companies with the capital, expertise, and partnerships needed to bridge the gap between discovery and clinical success. More Than Capital—An Execution Powerhouse Unlike traditional investors, we go beyond funding. We partner with biotech leaders to de-risk clinical trials, optimize financial strategy, and provide hands-on execution support, ensuring your therapy advances with confidence. What sets us apart? ✔ Non-Traditional Investment – Align capital with milestone-based funding to drive investor confidence ✔ Strategic CRO Partnership – Develop your clinical trial with Novotech, Biotech's Partner at Every Phase, to ensure successful trial execution ✔ Regulatory Expertise – Navigate the clinical trial roadmap with our trusted advisors and leverage global incentives, like Australia's RDTI ✔ Investor-Backed Positioning – Build confidence and credibility to ensure a strong market exit strategy Who We Work With We partner with select biotech startups that meet the following criteria: ✔ Within 18 months of entering clinical trials, with preclinical work completed or nearing completion. ✔ Haven’t chosen a CRO and are open to discussions with Novotech. ✔ Have at least 50% of required funding secured, including 5 Horizons’ contribution and a lead anchor investor. Led by Experts. Built for Biotech Success. Aaron Ray and Bill Cronin founded 5 Horizons to solve the biggest funding and execution gaps in biotech. Our team brings deep industry expertise, investment acumen, and operational insight, making us the strategic partner biotech startups trust to move forward. Your breakthrough therapy deserves more than capital—it deserves the right execution strategy to reach patients faster.